HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kaoru Nakao Selected Research

TRK 820

1/2016Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
11/2012In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
11/2010[Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
5/2010[Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
10/2009TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
5/2009Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
3/2009Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
4/2008[Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
8/2005Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
4/2004Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kaoru Nakao Research Topics

Disease

8Pruritus (Itching)
01/2016 - 08/2005
2Schizophrenia (Dementia Praecox)
11/2010 - 03/2009
2Dyskinesias (Dyskinesia)
11/2010 - 10/2009
2Pain (Aches)
11/2010 - 04/2004
2Dermatitis
04/2008 - 08/2005
1Liver Diseases (Liver Disease)
01/2016
1Overactive Urinary Bladder (Overactive Bladder)
03/2012
1Neuralgia (Stump Neuralgia)
11/2010
1Substance-Related Disorders (Drug Abuse)
11/2010
1Parkinson Disease (Parkinson's Disease)
10/2009
1Cough
09/2008
1Atopic Dermatitis (Atopic Eczema)
04/2008
1Autoimmune Diseases (Autoimmune Disease)
08/2005
1Hyperalgesia
04/2004

Drug/Important Bio-Agent (IBA)

10TRK 820IBA
01/2016 - 04/2004
7kappa Opioid Receptors (kappa Opioid Receptor)IBA
11/2010 - 04/2004
6AntipruriticsIBA
01/2016 - 08/2005
3furanIBA
01/2016 - 10/2009
3Pharmaceutical PreparationsIBA
03/2012 - 05/2009
2Opioid Receptors (Opioid Receptor)IBA
11/2012 - 05/2009
2MorphinansIBA
09/2008 - 04/2004
1Adenosine Monophosphate (AMP)IBA
11/2012
1Substance PIBA
11/2012
1ColforsinIBA
11/2012
1Adrenergic Receptors (Adrenergic Receptor)IBA
03/2012
1Narcotic Antagonists (Opioid Antagonists)IBA
09/2010
1Naltrexone (ReVia)FDA LinkGeneric
09/2010
1Oxidopamine (6 Hydroxydopamine)IBA
10/2009
1Levodopa (L Dopa)FDA LinkGeneric
10/2009
1Dopamine (Intropin)FDA LinkGeneric
10/2009
1Dihydrotachysterol (AT 10)IBA
10/2009
1norbinaltorphimineIBA
10/2009
1Phencyclidine (Angel Dust)IBA
03/2009
1methanesulfonic acid (methanesulfonate)IBA
09/2008
1delta Opioid Receptors (delta Opioid Receptor)IBA
09/2008
1Antitussive Agents (Antitussives)FDA Link
09/2008
1Histamine Antagonists (Antihistamines)IBA
04/2008
1Immunoglobulin E (IgE)IBA
08/2005
1Immunoglobulin G (IgG)IBA
08/2005
1mu Opioid Receptors (mu Opioid Receptor)IBA
04/2004
1enadolineIBA
04/2004
1Morphine (MS Contin)FDA LinkGeneric
04/2004

Therapy/Procedure

7Renal Dialysis (Hemodialysis)
01/2016 - 04/2008
1Therapeutics
10/2009
1Injections
04/2004